The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
58 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $29,952,327 in first-year total cost, median $300,000.
Most frequent study sections
- Special Emphasis Panel[ZRG1 IDM-V (12)]13
- Special Emphasis Panel[ZRG1 IMM-N (12)]13
- Special Emphasis Panel[ZRG1 IDM-U (10)]11
- HIV/AIDS Vaccines Study Section[VACC]5
- Special Emphasis Panel[ZRG1 IMM-G (10)]5
Most frequent institutions
- MAPP BIOPHARMACEUTICAL, INC.3
- MICROBIOTIX, INC3
- PROFECTUS BIOSCIENCES, INC.3
- ALTRAVAX, INC.2
- BREONICS, INC.2
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2015 | Broad Spectrum Antiviral Nucleoside Phosphonate Analogs2R44AI100401-03 | LIPKA, ELKE | TSRL, INC., MI | $997,904 | ZRG1 |
| 2015 | Development of a Universal Influenza B Vaccine1R43AI112264-01 | WHALEN, ROBERT G. | ALTRAVAX, INC., CA | $300,000 | ZRG1 |
| 2014 | The Potential to Immunocloak Renal Allografts2R44AI081372-03A1 | BRASILE, LAUREN | BREONICS, INC., NY | $1,000,000 | ZRG1 |
| 2014 | Rapid point of care test for Lyme serodiagnosis based on novel ultra sensitive de2R44AI091291-03 | KOVALENKO, VICTOR ANDREW | IMMUNETICS, INC., MA | $1,000,000 | ZRG1 |
| 2014 | An SEB Immunoprotectant2R44AI081392-03A1 | WHALEY, KEVIN JOHN | MAPP BIOPHARMACEUTICAL, INC., CA | $1,000,000 | ZRG1 |
| 2014 | Lab on a chip point of care assay for the rapid serodiagnosis of Lyme disease2R44AI096551-03 | GOMES-SOLECKI, MARIA | IMMUNO TECHNOLOGIES, INC., TN | $1,000,000 | ZRG1 |
| 2014 | Rapid Test for Recent HIV Infection2R44AI098567-03 | GARRETT, PATRICIA E | IMMUNETICS, INC., MA | $1,000,000 | ZRG1 |
| 2014 | Rapid, disposable, nucleic acid diagnostic device for multiplexed point of care f2R44AI093018-03A1 | CAI, HONG | MESA TECH INTERNATIONAL, INC., CA | $1,000,000 | ZRG1 |
| 2014 | Cryopreservation of Anopheles Embryos2R44AI088853-03A1 | BILLINGSLEY, PETER F. | SANARIA, INC., MD | $999,998 | ZRG1 |
| 2014 | Diagnostic array for aseptic encephalitis2R44AI085650-02A1 | CHANDLER, DARRELL PCOONEY, CHRISTOPHER GERARDST. GEORGE, KIRSTEN | AKONNI BIOSYSTEMS, INC., MD | $999,998 | ZRG1 |
| 2014 | An Immunoprotectant for Marburg Virus2R44AI082744-03 | ZEITLIN, LARRY | MAPP BIOPHARMACEUTICAL, INC., CA | $999,998 | ZRG1 |
| 2014 | Novel spectinamide antibiotics for the treatment of MDR/XDR tuberculosis2R44AI098271-03 | BUTLER, MICHELLE M. | MICROBIOTIX, INC, MA | $999,980 | ZRG1 |
| 2014 | Advancing a Mucosal HSV-2 Vaccine Towards Clinical Trials2R44AI063820-06 | YANG, KEJIAN | BIOMEDICAL RESEARCH MODELS, INC., MA | $999,834 | ZRG1 |
| 2014 | Multiplexed Bead-based In Vitro Pediatric Allergy Test2R44AI100424-03 | LIM, MARK | AMBERGEN, INC, MA | $998,905 | ZRG1 |
| 2014 | Recombinant antigen diagnostics for filoviruses2R44AI088843-03A1 | PITTS, KELLY R | CORGENIX MEDICAL CORPORATION, CO | $995,262 | ZRG1 |
| 2014 | A human cytomegalovirus-based immunotherapy for HIV-12R44AI100343-02 | BRUENING, ERIC | TOMEGAVAX, INC., OR | $992,696 | VACC |
| 2014 | Electrical System for Rapidly Detecting Viable Bacteria in Blood Culture2R44AI096572-02 | BOLAND, EUGENE DAVID | TECHSHOT, INC., IN | $961,155 | ZRG1 |
| 2014 | TITER ON CHIP: ALTERNATIVE TO SRID FOR INFLUENZA VACCINE POTENCY DETERMINATION2R44AI102318-03A1 | ROWLEN, KATHY L | INDEVR, INC., CO | $960,145 | ZRG1 |
| 2014 | Development of the first HRV vaccine2R44AI085683-03A1 | TOBIN, GREGORY JOHN | BIOLOGICAL MIMETICS, INC., MD | $923,094 | ZRG1 |
| 2014 | A serologic assay to measure successful Lyme borreliosis antibiotic therapy2R44AI085725-02A1 | LEDIZET, MICHEL | L2 DIAGNOSTICS, LLC, CT | $883,404 | ZRG1 |
| 2014 | Cell therapy for Repairing Warm Ischemically Damaged Kidneys1R43AI106362-01A1 | BRASILE, LAUREN | BREONICS, INC., NY | $300,000 | ZRG1 |
| 2014 | INNOVATIVE OPTICAL SYSTEM FOR HEMAGGLUTINATION ASSAYS1R43AI106054-01A1 | ROWLEN, KATHY L | INDEVR, INC., CO | $300,000 | ZRG1 |
| 2014 | In vivo conjugated multivalent toxoid-polysaccharide vaccine for S. aureus1R43AI106162-01A1 | ADHIKARI, RAJAN P | INTEGRATED BIOTHERAPEUTICS, INC., MD | $300,000 | ZRG1 |
| 2014 | Anti-virulence FimH inhibitors for the treatment and prevention of UTIs1R43AI106112-01A1 | CUSUMANO, ZACHARY | FIMBRION THERAPEUTICS, INC., MO | $300,000 | ZRG1 |
| 2014 | Enhanced Efficacy Photodynamic Disinfection1R43AI109938-01 | LALWANI, SANJIV | LYNNTECH, INC., TX | $300,000 | ZRG1 |
| 2014 | Development of a novel test for the early detection of Dengue Virus infection1R43AI109869-01 | PENA, JOSESTEIN, EMILY ANN | SEVIDENT, INC., CA | $300,000 | ZRG1 |
| 2014 | Immuno-Chemotherapy to Shorten TB Treatment1R43AI109936-01 | COLER, RHEA N | PAI LIFE SCIENCES, INC., WA | $300,000 | ZRG1 |
| 2014 | N-acetylglucosamine analogs for the treatment of Multiple Sclerosis.1R43AI106168-01A1 | OGANESYAN, ANI | GLIXIS THERAPEUTICS, LLC, CA | $300,000 | ZRG1 |
| 2014 | Optimization of Arenavirus Antivirals1R43AI112097-01 | MCCORMACK, KEN JPLEWE, MICHAEL BRUNO | ARISAN THERAPEUTICS, INC., CA | $300,000 | ZRG1 |
| 2014 | Nucleoside Phosphonate Analogs for the Treatment of Adenoviral Infection1R43AI112185-01 | LIPKA, ELKE | TSRL, INC., MI | $300,000 | ZRG1 |
| 2014 | Novel Subunit Vaccines against Varicella Zoster Virus1R43AI112141-01 | MESSAOUDI, ILHEMWHALEN, ROBERT G. | ALTRAVAX, INC., CA | $300,000 | ZRG1 |
| 2014 | Rapid No-Spin Chlamydia RNA Extraction via Filtering, Lysis and Monolith Binding1R43AI108062-01A1 | DROITCOUR, AMY | WAVE 80 BIOSCIENCES, INC., CA | $300,000 | ZRG1 |
| 2014 | Antibiotics for Recalcitrant Infection1R44AI112187-01A1 | COLEMAN, KENNETH | ARIETIS, MA | $300,000 | ZRG1 |
| 2014 | A human monoclonal for RSV prophylaxis1R43AI114069-01 | ZEITLIN, LARRY | MAPP BIOPHARMACEUTICAL, INC., CA | $300,000 | ZRG1 |
| 2014 | Development of Flavivirus Antivirals Targeting Dengue Virus and WNV Protease1R43AI114084-01 | PRASAD, SRIDHAR G | PLEX PHARMACEUTICALS, INC., CA | $300,000 | ZRG1 |
| 2014 | Optimization of a Therapeutic HIVSIV Multi-Antigen DNA Vaccine1R44AI110315-01A1 | BAGLEY, KENNETH C | PROFECTUS BIOSCIENCES, INC., MD | $300,000 | VACC |
| 2014 | An HIV Vaccine Strategy Based on Priming with rVSV Expressing FLSC1R44AI114319-01 | FOUTS, TIMOTHY R | PROFECTUS BIOSCIENCES, INC., MD | $300,000 | VACC |
| 2014 | Genetic Scaffolds Targeting the HIV Glycan Shield for an HIV Vaccine.1R43AI112484-01A1 | GENG, YU | PROSCI, INC., CA | $300,000 | VACC |
| 2014 | Automating mosquito microdissection for a malaria PfSPZ vaccine1R43AI112165-01 | HOFFMAN, STEPHEN LEV | SANARIA, INC., MD | $299,999 | ZRG1 |
| 2014 | Antimicrobial Microbead Containing Topical Gel for Burn Wound Disinfection1R43AI113950-01 | LALWANI, SANJIV | LYNNTECH, INC., TX | $299,994 | ZRG1 |
| 2014 | Twist-Sensor: Novel microarrays for multiplex detection of drug resistance1R43AI109930-01 | CELEDON, ALFREDO ANDRES | SCANOGEN, INC., MD | $299,940 | ZRG1 |
| 2014 | Malarial Retinopathy Screening System for Improved Diagnosis of Cerebral Malaria1R43AI112164-01 | JOSHI, VINAYAK SLEWALLEN, SUSAN | VISIONQUEST BIOMEDICAL, LLC, NM | $299,904 | ZRG1 |
| 2014 | Therapeutic/preventive vaccination against MusPV1R43AI112421-01 | CHANG, YUNG-NIEN | PAPIVAX, LLC, MD | $299,802 | ZRG1 |
| 2014 | Selective agents against C. difficile infection1R43AI108042-01A1 | HUGHES, DALLAS | NOVOBIOTIC PHARMACEUTICALS, LLC, MA | $299,684 | ZRG1 |
| 2014 | Broad-spectrum, orally-bioavailable beta-lactamase inhibitors1R43AI109879-01 | CHU, GUO-HUA | VENATORX PHARMACEUTICALS, INC., PA | $299,600 | ZRG1 |
| 2014 | Direct visualization assay for detection of B. burgdorferi in early Lyme Disease1R43AI113990-01 | KALDJIAN, ERIC | RARECYTE, INC., WA | $299,501 | ZRG1 |
| 2014 | A Culture-Free Platform for Rapid Pathogen Identification1R43AI109913-01 | SINGER, ALON | HELIXBIND, INC., MA | $299,310 | ZRG1 |
| 2014 | Dityrosine Locked Prefusion F Protein: A Path To A Protective RSV Vaccine1R43AI112124-01A1 | MARIANI, ROBERTOMCLELLAN, JASON SCOTT | AVATAR MEDICAL, LLC, NY | $298,852 | ZRG1 |
| 2014 | Strain-Independent Therapeutic Antibodies for Influenza1R44AI106077-01A1 | KAUVAR, LAWRENCE MICHAEL | TRELLIS BIOSCIENCE, INC., CA | $298,735 | ZRG1 |
| 2014 | Small Molecule Inhibitors of trans-Translation with Broad Spectrum Antibacterial1R43AI113993-01 | WILLIAMS, JOHN D | MICROBIOTIX, INC, MA | $295,584 | ZRG1 |
| 2014 | A Novel Vaccine to Prevent Urinary Tract Infections1R43AI109845-01A1 | CATRON, DREW | SYNTIRON, LLC., MN | $294,002 | ZRG1 |
| 2014 | Novel Inhibitors Targeting Early Steps of Human Cytomegalovirus Replication1R43AI113971-01 | KOMAZIN-MEREDITH, GLORIA | MICROBIOTIX, INC, MA | $293,541 | ZRG1 |
| 2014 | Point-of-care immunoassay for early diagnosis of pertussis1R43AI109891-01A1 | BURNHAM-MARUSICH, AMANDAKOZEL, THOMAS R | DXDISCOVERY, INC., NV | $292,091 | ZRG1 |
| 2014 | Transcriptional silencing of latent HIV infection - a novel small molecule class1R43AI110186-01A1 | BARAN, PHIL SMACHERLA, VENKATAUSUI, IPPEIVALENTE, SUSANA T | SIRENAS MARINE DISCOVERY, LLC, CA | $291,941 | ADDT |
| 2014 | Stable Vaccines Delivered on Oral Thin Films1R43AI108083-01A1 | TRUONG, VU L. | ARIDIS PHARMACEUTICALS, LLC, CA | $283,500 | ZRG1 |
| 2014 | TN-LAMP-vax: a Multi-Valent Tree Nut Allergy Immunotherapy1R43AI113914-01 | HEILAND, THERESE L | IMMUNOMIC THERAPEUTICS, INC., PA | $255,217 | ZRG1 |
| 2014 | Optimization of an innate immune stimulating adjuvant for an HIV DNA vaccine1R43AI114331-01 | BAGLEY, KENNETH C | PROFECTUS BIOSCIENCES, INC., MD | $238,756 | VACC |
| 2014 | Safe and Efficacious Oral MIF Inhibitors for Rheumatoid Arthritis2R44AI096570-03 | GAWECO, ANDERSON | INNOVIMMUNE BIOTHERAPEUTICS, INC., NY | $1 | ZRG1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.